Forest systems cover more than 4.1 x 10(9) hectares of the Earth's land area. Globally, forest vegetation and soils contain about 1146 petagrams of carbon, with approximately 37 percent of this carbon in low-latitude forests, 14 percent in mid-latitudes, and 49 percent at high latitudes. Over two-thirds of the carbon in forest ecosystems is contained in soils and associated peat deposits. In 1990, deforestation in the low latitudes emitted 1.6 +/- 0.4 petagrams of carbon per year, whereas forest area expansion and growth in mid- and high-latitude forest sequestered 0.7 +/- 0.2 petagrams of carbon per year, for a net flux to the atmosphere of 0.9 +/- 0.4 petagrams of carbon per year. Slowing deforestation, combined with an increase in forestation and other management measures to improve forest ecosystem productivity, could conserve or sequester significant quantities of carbon. Future forest carbon cycling trends attributable to losses and regrowth associated with global climate and land-use change are uncertain. Model projections and some results suggest that forests could be carbon sinks or sources in the future.

No abstract

AICA-riboside (5-amino-4-imidazole carboxamide ribonucleoside) is a novel adenosine-regulating agent that is currently being investigated for the treatment of ischemic heart disease. In a placebo-controlled, double-blind study in healthy men, we evaluated the safety and kinetics of the drug after oral and IV administration of 10, 25, 50, and 100 mg/kg doses. At each dose level, four subjects received active drug and two subjects received placebo with a 1-week wash-out period between the IV and oral doses. The drug was well tolerated at all dose levels with only mild and transient side effects reported in some instances by the subjects who received placebo and those patients who received the drug. The post-infusion plasma concentrations of AICA-riboside declined rapidly in a biphasic fashion, and the terminal elimination phase had a harmonic mean t1/2 beta of 1.4 hours. Total plasma clearance (CL), mean residence time (MRTIV), and volume of distribution at steady-state (VSS) were 2.5 L/hr/kg, 0.7 hr, and 1.6 L/kg, respectively. The drug was not protein bound, and there was rapid uptake and phosphorylation in RBCs to its 5'-monophosphate nucleotide. Renal clearance (CLR) was 0.2 L/hr/kg with only 8% of the IV dose excreted in the urine as intact AICA-riboside. Although there was a trend towards a decrease in CL with increasing dose, there were no significant differences (P greater than .05) in the mean estimates of t1/2 beta, CL, CLR, MRTIV and VSS associated with dose. The drug was poorly bioavailable (less than 5%) when administered orally in solution.

No abstract